title: Chronic toxicity of thiabendazole (TBZ) in CD-1 mice.
abstract: Male and female CD-1 mice (50 mice per group) were administered thiabendazole (TBZ) in diet at levels of 0 (control), 0.031, 0.125 and 0.5% for 78 weeks. A life time study was terminated after 78 weeks due to enhanced strain specific mortality. There were no significant differences in mortality between the control and treated groups. Mean body weights of high-dose groups showed significant decreases compared with the controls. The bladder weights of male and female mice of the 0.5% group were significantly higher than those of the control mice. Gross findings in treated mice included the renal atrophy, hydronephrosis, calculi in renal pelvis and/or bladder and ovarian atrophy. Microscopic findings in the kidneys of treated mice included the nephrosis, hydronephrosis or hyperplasia of transitional epithelium of renal pelvis or papilla. In the bladder of treated mice, hyperplasia or squamous metaplasia of transitional epithelium and one transitional cell papilloma were observed. Dose-dependent decreases in the incidence of spontaneous lesion in the male or female reproductive system were recognized. It is concluded that TBZ is not carcinogenic to CD-1 mice of both sexes. However, caution should be exercised in the long-term application of high TBZ doses.
authors.affiliation: Department of Toxicology, Tokyo Metropolitan Research Laboratory of Public Health, 24-1, Hyakunincho 3-chome, Shinjuku-ku, 169-0073, Tokyo, Japan. tada@tokyo-eiken.go.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Tada
authors.forename: T
authors.initials: T
authors.lastname: Fujitani
authors.forename: N
authors.initials: N
authors.lastname: Yano
authors.forename: K
authors.initials: K
authors.lastname: Yuzawa
authors.forename: A
authors.initials: A
authors.lastname: Nagasawa
authors.forename: N
authors.initials: N
authors.lastname: Aoki
authors.forename: A
authors.initials: A
authors.lastname: Ogata
authors.forename: M
authors.initials: M
authors.lastname: Yoneyama
mesh_terms: D000284:Administration, Oral; D000818:Animals; D021461:Animals, Outbred Strains; D001792:Blood Platelets / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D015197:Carcinogenicity Tests; D003872:Dermatitis; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D005260:Female; D006197:Hair / Q000187:drug effects; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D007674:Kidney Diseases / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009369:Neoplasms / Q000139:chemically induced* / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D010976:Platelet Count; D012737:Sex Factors; D015996:Survival Rate; D013827:Thiabendazole / Q000008:administration & dosage / Q000633:toxicity*; D013995:Time; D014551:Urinary Tract / Q000187:drug effects* / Q000473:pathology
chemical_list: D013827:Thiabendazole